Cmp Dev Llc Company Profile

✉ Email this page to a colleague

CMP DEV LLC has six approved drugs.

There are nineteen US patents protecting CMP DEV LLC drugs.

There are sixteen patent family members on CMP DEV LLC drugs in nine countries and fifty-two supplementary protection certificates in eleven countries.

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cmp Dev Llc	NORLIQVA	amlodipine besylate	SOLUTION;ORAL	214439-001	Feb 24, 2022		RX	Yes	Yes	11,723,866	⤷ Try a Trial	Y			⤷ Try a Trial
Cmp Dev Llc	CAROSPIR	spironolactone	SUSPENSION;ORAL	209478-001	Aug 4, 2017	AB	RX	Yes	Yes	11,395,828	⤷ Try a Trial				⤷ Try a Trial
Cmp Dev Llc	CAROSPIR	spironolactone	SUSPENSION;ORAL	209478-001	Aug 4, 2017	AB	RX	Yes	Yes	10,624,906	⤷ Try a Trial	Y			⤷ Try a Trial
Cmp Dev Llc	LIQREV	sildenafil citrate	SUSPENSION;ORAL	214952-001	Apr 28, 2023		RX	Yes	Yes	11,464,778	⤷ Try a Trial	Y			⤷ Try a Trial
Cmp Dev Llc	NORLIQVA	amlodipine besylate	SOLUTION;ORAL	214439-001	Feb 24, 2022		RX	Yes	Yes	11,458,095	⤷ Try a Trial	Y			⤷ Try a Trial
Cmp Dev Llc	CAROSPIR	spironolactone	SUSPENSION;ORAL	209478-001	Aug 4, 2017	AB	RX	Yes	Yes	9,757,394	⤷ Try a Trial	Y			⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2017075463	⤷ Try a Trial
Singapore	11202006080S	⤷ Try a Trial
European Patent Office	3468606	⤷ Try a Trial
China	111683683	⤷ Try a Trial
European Patent Office	3368045	⤷ Try a Trial
World Intellectual Property Organization (WIPO)	2017212409	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0247633	97C0103	Belgium	⤷ Try a Trial	PRODUCT NAME: CALCII ATORVASTATINUM TRIHYDRICUM (=ATORVASTATINUM); NAT. REGISTRATION NO/DATE: 19 IS 95 F 3 19970922; FIRST REGISTRATION: GB PL/00018/0240 19961107
0253310	SPC/GB95/010	United Kingdom	⤷ Try a Trial	PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
2101777	2016C/032	Belgium	⤷ Try a Trial	PRODUCT NAME: AMBRISENTAN EN COMBINAISON AVEC LE TADALAFIL; AUTHORISATION NUMBER AND DATE: EU/1/08/451 20151125
1441735	08C0026	France	⤷ Try a Trial	PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102
0720599	300689	Netherlands	⤷ Try a Trial	PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912
0740668	C00740668/01	Switzerland	⤷ Try a Trial	PRODUCT NAME: TADALAFILUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56018 04.05.2004
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.